Woodline Partners LP Buys 20,684 Shares of Zoetis Inc. $ZTS

Key Points

• Woodline Partners LP increased its stake in Zoetis Inc. by 120.6%, acquiring an additional 20,684 shares, bringing its total holdings to 37,832 shares valued at approximately $6.23 million.
• Zoetis reported $1.76 earnings per share for the latest quarter, surpassing expectations, with revenue reaching $2.46 billion, marking a 4.2% increase from the previous year.
• The stock currently has a consensus rating of "Moderate Buy" from analysts, with an average price target of $200.88, reflecting positive sentiment despite recent downgrades from some research firms.

Woodline Partners LP raised its stake in shares of Zoetis Inc. (NYSE:ZTS - Free Report) by 120.6% during the 1st quarter, according to the company in its most recent filing with the SEC. The firm owned 37,832 shares of the company's stock after purchasing an additional 20,684 shares during the quarter. Woodline Partners LP's holdings in Zoetis were worth $6,229,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds also recently made changes to their positions in the stock. Vanguard Group Inc. increased its holdings in shares of Zoetis by 0.5% during the 1st quarter. Vanguard Group Inc. now owns 41,556,164 shares of the company's stock worth $6,842,222,000 after purchasing an additional 189,287 shares during the period. Polen Capital Management LLC increased its stake in Zoetis by 17.6% in the first quarter. Polen Capital Management LLC now owns 8,796,847 shares of the company's stock valued at $1,448,401,000 after acquiring an additional 1,313,653 shares during the period. Northern Trust Corp increased its stake in Zoetis by 1.2% in the first quarter. Northern Trust Corp now owns 6,504,902 shares of the company's stock valued at $1,071,032,000 after acquiring an additional 78,508 shares during the period. Goldman Sachs Group Inc. grew its stake in Zoetis by 2.2% during the first quarter. Goldman Sachs Group Inc. now owns 5,146,024 shares of the company's stock worth $847,293,000 after buying an additional 109,791 shares during the last quarter. Finally, Brown Advisory Inc. grew its stake in Zoetis by 7.6% during the first quarter. Brown Advisory Inc. now owns 4,408,542 shares of the company's stock worth $725,866,000 after buying an additional 312,746 shares during the last quarter. Institutional investors own 92.80% of the company's stock.

Zoetis Trading Down 1.5%

ZTS opened at $148.33 on Friday. The firm's fifty day moving average is $152.32 and its two-hundred day moving average is $157.31. The company has a debt-to-equity ratio of 1.05, a quick ratio of 1.04 and a current ratio of 1.76. The firm has a market cap of $65.74 billion, a PE ratio of 25.53, a price-to-earnings-growth ratio of 2.42 and a beta of 0.89. Zoetis Inc. has a twelve month low of $139.70 and a twelve month high of $200.33.

Zoetis (NYSE:ZTS - Get Free Report) last posted its earnings results on Tuesday, August 5th. The company reported $1.76 earnings per share for the quarter, topping the consensus estimate of $1.62 by $0.14. The company had revenue of $2.46 billion for the quarter, compared to analyst estimates of $2.41 billion. Zoetis had a net margin of 27.83% and a return on equity of 56.90%. The business's revenue for the quarter was up 4.2% compared to the same quarter last year. During the same period last year, the business posted $1.56 earnings per share. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. Equities research analysts anticipate that Zoetis Inc. will post 6.07 EPS for the current year.

Wall Street Analyst Weigh In

Several analysts have weighed in on ZTS shares. Leerink Partnrs cut shares of Zoetis from a "strong-buy" rating to a "hold" rating in a research note on Thursday, July 17th. Leerink Partners lowered Zoetis from an "outperform" rating to a "market perform" rating and cut their price target for the company from $180.00 to $155.00 in a research note on Thursday, July 17th. Stifel Nicolaus lowered Zoetis from a "buy" rating to a "hold" rating and cut their price target for the company from $165.00 to $160.00 in a research note on Wednesday, June 18th. Argus reaffirmed a "buy" rating and issued a $190.00 price objective on shares of Zoetis in a research note on Tuesday. Finally, Piper Sandler raised their price objective on shares of Zoetis from $210.00 to $215.00 and gave the company an "overweight" rating in a research note on Monday, August 11th. Five equities research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company's stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $200.88.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.

Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTS - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.